New hope for hemophilia b: trial tests Long-Acting clotting factor in chinese patients
NCT ID NCT05365217
First seen Jan 12, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study tested a medicine called nonacog beta pegol (N9-GP) in 30 Chinese men with moderate to severe hemophilia B. The medicine is injected into a vein to help blood clot and prevent or treat bleeding episodes. The trial lasted about 12-16 months and checked how well the medicine worked and how safe it was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, 100045, China
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
-
Fujian Medical University Union Hospital-Hematology
Fuzhou, Fujian, 350001, China
-
Henan Cancer Hospital-Hematology
Zhengzhou, Henan, 450003, China
-
Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology
Tianjin, Tianjin Municipality, 300020, China
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
Nanfang Hospital, Southern Medical University-Haematology
Guangzhou, Guangdong, 510515, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
The Affiliated Hospital of Guizhou Medical University-Hematology
Guiyang, Guizhou, 550004, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266555, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650101, China
-
Tongji Hospital, Tongji Medical College of HUST-Hematology
Wuhan, Hubei, 430030, China
-
Xiangya Hospital Central-South University
Changsha, Hunan, 410008, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nonacog beta pegol (a clotting factor IX medicine)
What this could lead to
If successful, this could provide a safe and effective option for Chinese patients with hemophilia B to control and prevent bleeding episodes.
What could go wrong
This is a small, completed phase 3 trial with only 30 participants, so results may not apply to all patients. The medicine is already approved elsewhere, but its long-term safety and effectiveness in this specific population need confirmation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.